Tejara Capital Ltd Buys New Position in Maravai LifeSciences Holdings, Inc. $MRVI

Key Points

• Tejara Capital Ltd invested approximately $1.20 million in Maravai LifeSciences by purchasing 542,549 shares during the first quarter, representing about 0.21% of the company's stock.
• Maravai LifeSciences reported a quarterly EPS of ($0.08), missing analyst estimates by $0.01, with revenues down 26.9% year-over-year.
• Analysts have set a consensus price target of $5.75 for Maravai LifeSciences, with ratings ranging from one sell to four buy ratings.

Tejara Capital Ltd acquired a new stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 542,549 shares of the company's stock, valued at approximately $1,199,000. Tejara Capital Ltd owned 0.21% of Maravai LifeSciences at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Teacher Retirement System of Texas bought a new position in shares of Maravai LifeSciences in the first quarter worth approximately $37,000. Aigen Investment Management LP bought a new position in Maravai LifeSciences in the 1st quarter worth $37,000. Performa Ltd US LLC boosted its holdings in Maravai LifeSciences by 245.0% in the 1st quarter. Performa Ltd US LLC now owns 17,250 shares of the company's stock worth $38,000 after buying an additional 12,250 shares during the period. Pekin Hardy Strauss Inc. bought a new position in Maravai LifeSciences in the 1st quarter worth $55,000. Finally, Simplicity Wealth LLC bought a new position in Maravai LifeSciences in the 1st quarter worth $67,000. Institutional investors own 50.25% of the company's stock.

Maravai LifeSciences Trading Down 2.0%

Shares of NASDAQ:MRVI traded down $0.05 during trading on Wednesday, hitting $2.46. The company had a trading volume of 1,094,000 shares, compared to its average volume of 1,609,713. The stock has a market cap of $626.46 million, a price-to-earnings ratio of -1.81 and a beta of 0.28. Maravai LifeSciences Holdings, Inc. has a one year low of $1.66 and a one year high of $9.60. The company has a fifty day simple moving average of $2.44 and a two-hundred day simple moving average of $2.55. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.16 and a quick ratio of 4.49.

Wall Street Analyst Weigh In

MRVI has been the subject of several recent analyst reports. Royal Bank Of Canada dropped their price target on Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating for the company in a research note on Tuesday, August 12th. Robert W. Baird dropped their target price on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Finally, Craig Hallum dropped their target price on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Four research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $5.75.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.